Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Patients with stage IV or recurrent stage I-III NSCLC with documented disease control (objective response or stable disease) within 3 weeks after platinum based 1st line chemotherapy; only HLA-A*0201 positive patients with TERT expressing tumors will be included. The objective of the trial is survival rate at 12 months.
Critère d'inclusion
- Non-small Cell Lung Cancer Metastatic